Since the approval of the first gene therapy for blindness, there has been a wave of companies developing gene therapy treatments with the potential to cure different forms of genetic…
While there is no doubt that Europe has a thriving biotech scene, it can really help a European company to succeed if it has a US presence. No one knows…
The French company Eyevensys has raised €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis…
Over 10,000 human diseases are caused by exactly one faulty gene. Gene therapy promises to fix each of them. Here's a review of biotech's progress. Biotech is arguably built on genetic…
Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β…
Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company's CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris…
Eyevensys has received regulatory approval in France to start clinical trials using eye gene therapy technology that eliminates the need for viral vectors. The French biotech Eyevensys has been cleared…